ALK and lung carcinoma: developed MS4078 (Figure 33), a ceritinib-based PROTAC targeting ALK fusion proteins, which demonstrated significant concentration- and time-dependent ALK degradation in SU-DHL-1 lymphoma (DC50 = 11.0 nM) and NCI-H2228 lung cancer cells (DC50 = 59.0 nM).